TOCILIZUMAB IN FIRST LINE BIOLOGIC TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE IN POLAND - MULTICENTER, NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY (ACT-POL)
Phase of Trial: Phase IV
Latest Information Update: 21 Sep 2016
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ACT-POL
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 12 Sep 2016 Status changed from active, no longer recruiting to completed.
- 02 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.